Table 1 Demographic and clinical characteristics of study patients with vitiligo (n = 294)
Variable n (%), median (min-max) | The study sample (n = 294) |
|---|---|
Age, years | 35 (3–86) |
< 18 | 35 (11.9) |
18–39 | 153 (52.0) |
40–59 | 88 (29.9) |
60–79 | 17 (5.8) |
≥ 80 | 1 (0.3) |
Sex | Â |
Male | 133 (45.2) |
Female | 161 (54.8) |
Disease duration | 9 (0.10–54) |
Age at vitiligo onset | 24 (1–84) |
Course of the disease | Â |
Stationary | 67 (22.8) |
Regressive | 21 (7.1) |
Progressive | 206 (70.1) |
Affected BSA, % 1–25 | 134 (45.6) |
26–50 | 131 (44.6) |
51–75 | 16 (5.4) |
76–100 | 13 (4.4) |
Distribution | Â |
Face or body | 268 (91.2) |
Face and body | 26 (8.8) |
Laterality | Â |
Unilateral/midline | 241 (82.0) |
Bilateral | 53 (18.0) |
Family history of vitiligo | 62 (21.1) |
Family history of AIIDs | 74 (25.2) |
VIDA | Â |
+ 4 | 32 (10.9) |
+ 3 | 57 (19.4) |
+ 2 | 77 (26.2) |
+ 1 | 35 (11.9) |
0 | 32 (10.9) |
-1 | 61 (20.7 |
Treatment | Â |
No | 141 (48) |
Local | 131 (44.6) |
Systemic | 12 (4.1) |
Both local and systemic | 10 (3.4) |